Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lessened its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,146,769 shares of the biopharmaceutical company’s stock after selling 842,005 shares during the quarter. Federated Hermes Inc. owned approximately 5.46% of Dynavax Technologies worth $80,258,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DVAX. Duality Advisers LP acquired a new stake in Dynavax Technologies during the first quarter valued at $227,000. Natixis Advisors L.P. grew its position in shares of Dynavax Technologies by 10.5% in the fourth quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 1,804 shares during the period. Boston Partners acquired a new stake in shares of Dynavax Technologies in the first quarter valued at about $292,000. China Universal Asset Management Co. Ltd. grew its position in shares of Dynavax Technologies by 67.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 10,143 shares during the period. Finally, Choreo LLC acquired a new stake in shares of Dynavax Technologies in the second quarter valued at about $363,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

DVAX has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Wednesday, August 7th. The Goldman Sachs Group dropped their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Stock Performance

DVAX opened at $11.17 on Friday. The firm has a market capitalization of $1.46 billion, a PE ratio of 186.17 and a beta of 1.37. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.15. The firm’s 50-day moving average price is $11.00 and its 200 day moving average price is $11.54. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same period in the previous year, the business posted $0.03 earnings per share. As a group, sell-side analysts expect that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.